Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 55

1.

Cognitive performance during the first year of treatment in first-episode schizophrenia: a case-control study.

Olivier MR, Killian S, Chiliza B, Asmal L, Schoeman R, Oosthuizen PP, Kidd M, Emsley R.

Psychol Med. 2015 Oct;45(13):2873-83. doi: 10.1017/S0033291715000860. Epub 2015 May 22.

PMID:
25998030
2.

Changes in body mass and metabolic profiles in patients with first-episode schizophrenia treated for 12 months with a first-generation antipsychotic.

Chiliza B, Asmal L, Oosthuizen P, van Niekerk E, Erasmus R, Kidd M, Malhotra A, Emsley R.

Eur Psychiatry. 2015 Feb;30(2):277-83. doi: 10.1016/j.eurpsy.2014.11.013. Epub 2015 Jan 7.

PMID:
25577186
3.

Combining depot antipsychotic with an assertive monitoring programme for treating first-episode schizophrenia in a resource-constrained setting.

Chiliza B, Ojagbemi A, Esan O, Asmal L, Oosthuizen P, Kidd M, Gureje O, Emsley R.

Early Interv Psychiatry. 2016 Feb;10(1):54-62. doi: 10.1111/eip.12141. Epub 2014 Apr 1.

PMID:
24690088
4.

Comparison of treatment response in second-episode versus first-episode schizophrenia.

Emsley R, Oosthuizen P, Koen L, Niehaus D, Martinez L.

J Clin Psychopharmacol. 2013 Feb;33(1):80-3. doi: 10.1097/JCP.0b013e31827bfcc1.

PMID:
23277247
5.

Symptom recurrence following intermittent treatment in first-episode schizophrenia successfully treated for 2 years: a 3-year open-label clinical study.

Emsley R, Oosthuizen PP, Koen L, Niehaus DJ, Martinez G.

J Clin Psychiatry. 2012 Apr;73(4):e541-7. doi: 10.4088/JCP.11m07138.

PMID:
22579160
6.

Diagnostic outcome of patients referred to psychiatry with medically unexplained symptoms: a retrospective study.

Govender RC, Oosthuizen P, Cloete KJ.

Afr J Psychiatry (Johannesbg). 2011 Mar;14(1):45-9.

PMID:
21509409
7.

Assessing the efficacy of a modified assertive community-based treatment programme in a developing country.

Botha UA, Koen L, Joska JA, Hering LM, Oosthuizen PP.

BMC Psychiatry. 2010 Sep 15;10:73. doi: 10.1186/1471-244X-10-73.

8.

Subjective awareness of tardive dyskinesia and insight in schizophrenia.

Emsley R, Niehaus DJ, Oosthuizen PP, Koen L, Chiliza B, Fincham D.

Eur Psychiatry. 2011 Jul-Aug;26(5):293-6. doi: 10.1016/j.eurpsy.2009.12.006. Epub 2010 Jul 8.

PMID:
20615668
9.

Pathways to inpatient mental health care among people with schizophrenia spectrum disorders in South Africa.

Lund C, Oosthuizen P, Flisher AJ, Emsley R, Stein DJ, Botha U, Koen L, Joska J.

Psychiatr Serv. 2010 Mar;61(3):235-40. doi: 10.1176/ps.2010.61.3.235.

PMID:
20194399
10.
11.

Changes in erythrocyte membrane fatty acids during a clinical trial of eicosapentaenoic acid (EPA) supplementation in schizophrenia.

van Rensburg SJ, Smuts CM, Hon D, Kidd M, van der Merwe S, Myburgh C, Oosthuizen P, Emsley R.

Metab Brain Dis. 2009 Dec;24(4):659-72. doi: 10.1007/s11011-009-9160-7. Epub 2009 Oct 14.

PMID:
19826937
12.

Assertive community treatment in the South African context.

Botha U, Koen L, Oosthuizen P, Joska J, Hering L.

Afr J Psychiatry (Johannesbg). 2008 Nov;11(4):272-5.

PMID:
19588049
13.

The multidimensional assessment of psychopathology in mood and psychotic disorders. A proposal for Axis II in DSM-V/ICD-11.

Oosthuizen P, Emsley R, Niehaus D, Koen L.

Afr J Psychiatry (Johannesbg). 2008 Nov;11(4):260-3.

PMID:
19588047
14.

The revolving door phenomenon in psychiatry: comparing low-frequency and high-frequency users of psychiatric inpatient services in a developing country.

Botha UA, Koen L, Joska JA, Parker JS, Horn N, Hering LM, Oosthuizen PP.

Soc Psychiatry Psychiatr Epidemiol. 2010 Apr;45(4):461-8. doi: 10.1007/s00127-009-0085-6. Epub 2009 Jun 18.

PMID:
19536445
15.

Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.

Emsley R, Oosthuizen P, Koen L, Niehaus DJ, Medori R, Rabinowitz J.

Clin Ther. 2008 Dec;30(12):2378-86. doi: 10.1016/j.clinthera.2008.12.020.

PMID:
19167596
16.

Mass murders: implications for mental health professionals.

Aitken L, Oosthuizen P, Emsley R, Seedat S.

Int J Psychiatry Med. 2008;38(3):261-9.

PMID:
19069571
17.

Safety of the omega-3 fatty acid, eicosapentaenoic acid (EPA) in psychiatric patients: results from a randomized, placebo-controlled trial.

Emsley R, Niehaus DJ, Oosthuizen PP, Koen L, Ascott-Evans B, Chiliza B, van Rensburg SJ, Smit RM.

Psychiatry Res. 2008 Dec 15;161(3):284-91. doi: 10.1016/j.psychres.2007.06.029. Epub 2008 Oct 29.

PMID:
18962989
18.

Remission in patients with first-episode schizophrenia receiving assured antipsychotic medication: a study with risperidone long-acting injection.

Emsley R, Oosthuizen P, Koen L, Niehaus DJ, Medori R, Rabinowitz J.

Int Clin Psychopharmacol. 2008 Nov;23(6):325-31. doi: 10.1097/YIC.0b013e32830c2042.

PMID:
18854720
19.

Predictors of abnormal involuntary movement in an african schizophrenia population.

Niehaus DJ, du Plessis SA, Koen L, Lategan BH, Steyn J, Oosthuizen PP, Warnich L, Emsley RA.

J Neuropsychiatry Clin Neurosci. 2008 Summer;20(3):317-26. doi: 10.1176/appi.neuropsych.20.3.317.

PMID:
18806235
20.

Crisis discharges and readmission risk in acute psychiatric male inpatients.

Niehaus DJ, Koen L, Galal U, Dhansay K, Oosthuizen PP, Emsley RA, Jordaan E.

BMC Psychiatry. 2008 Jun 17;8:44. doi: 10.1186/1471-244X-8-44.

Supplemental Content

Loading ...
Support Center